Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

staar surgical - STAA

STAA

Close Chg Chg %
19.53 -0.11 -0.56%

Closed Market

19.42

-0.11 (0.56%)

Volume: 970.77K

Last Updated:

May 9, 2025, 4:00 PM EDT

Trade Now

Company Overview: staar surgical - STAA

STAA Key Data

Open

$19.72

 Day Range

19.33 - 19.98

52 Week Range

13.50 - 49.86

 Market Cap

$967.24M

Shares Outstanding

49.53M

 Public Float

49.16M

Beta

0.66

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.44

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

796.17K

  

STAA Performance

1 Week
 
 2.05%
 
1 Month
 
 15.66%
 
3 Months
 
 26.51%
 
1 Year
 
 -54.14%
 
5 Years
 
 -48.71%
 

STAA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About staar surgical - STAA

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

STAA At a Glance

STAAR Surgical Co.
25510 Commercentre Drive
Lake Forest, California 92630
Phone 1-626-303-7902 Revenue 313.90M
Industry Medical Specialties Net Income -20,208,000.00
Sector Health Technology Employees 1,211
Fiscal Year-end 12 / 2025
View SEC Filings

STAA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.789
Price to Book Ratio 3.004
Price to Cash Flow Ratio 75.632
Enterprise Value to EBITDA -174.40
Enterprise Value to Sales 3.178
Total Debt to Enterprise Value 0.039

STAA Efficiency

Revenue/Employee 259,208.092
Income Per Employee -16,687.036
Receivables Turnover 3.96
Total Asset Turnover 0.629

STAA Liquidity

Current Ratio 5.233
Quick Ratio 4.617
Cash Ratio 3.278

STAA Profitability

Gross Margin 74.978
Operating Margin -4.018
Pretax Margin -2.884
Net Margin -6.438
Return on Assets -4.049
Return on Equity -5.16
Return on Total Capital -4.634
Return on Invested Capital -4.757

STAA Capital Structure

Total Debt to Total Equity 9.751
Total Debt to Total Capital 8.884
Total Debt to Total Assets 7.604
Long-Term Debt to Equity 8.76
Long-Term Debt to Total Capital 7.982
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Staar Surgical - STAA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
230.47M 284.39M 322.42M 313.90M
Sales Growth
+41.00% +23.40% +13.37% -2.64%
Cost of Goods Sold (COGS) incl D&A
51.84M 61.01M 69.76M 78.55M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.64M 4.51M 5.12M 6.89M
Depreciation
3.61M 4.48M 5.11M 6.89M
Amortization of Intangibles
- 34.00K 28.00K 13.00K
COGS Growth
+18.08% +17.70% +14.35% +12.59%
Gross Income
178.64M 223.38M 252.65M 235.36M
Gross Income Growth
+49.41% +25.05% +13.10% -6.85%
Gross Profit Margin
+77.51% +78.55% +78.36% +74.98%
2021 2022 2023 2024 5-year trend
SG&A Expense
145.30M 179.64M 224.72M 247.98M
Research & Development
33.86M 35.98M 44.40M 53.29M
Other SG&A
111.44M 143.65M 180.32M 194.69M
SGA Growth
+30.07% +23.63% +25.10% +10.35%
Other Operating Expense
(5.00K) (55.00K) (171.00K) (9.00K)
Unusual Expense
- - - -
-
EBIT after Unusual Expense
33.34M 43.80M 28.10M (12.61M)
Non Operating Income/Expense
(2.00M) 1.75M 5.60M 3.56M
Non-Operating Interest Income
- 2.45M 6.99M 5.91M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 38.00K
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 38.00K
-
Interest Capitalized
- - - -
-
Pretax Income
31.30M 45.55M 33.70M (9.05M)
Pretax Income Growth
+278.66% +45.51% -26.03% -126.86%
Pretax Margin
+13.58% +16.02% +10.45% -2.88%
Income Tax
6.80M 6.80M 12.35M 11.16M
Income Tax - Current - Domestic
- - - 27.00K
-
Income Tax - Current - Foreign
5.31M 8.14M 9.09M 7.54M
Income Tax - Deferred - Domestic
845.00K (829.00K) 3.32M 3.88M
Income Tax - Deferred - Foreign
650.00K (515.00K) (54.00K) (285.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
24.50M 38.76M 21.35M (20.21M)
Minority Interest Expense
- - - -
-
Net Income
24.50M 38.76M 21.35M (20.21M)
Net Income Growth
+314.36% +58.18% -44.92% -194.66%
Net Margin Growth
+10.63% +13.63% +6.62% -6.44%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
24.50M 38.76M 21.35M (20.21M)
Preferred Dividends
- - - -
-
Net Income Available to Common
24.50M 38.76M 21.35M (20.21M)
EPS (Basic)
0.519 0.8076 0.4399 -0.4114
EPS (Basic) Growth
+300.15% +55.61% -45.53% -193.52%
Basic Shares Outstanding
47.21M 47.99M 48.52M 49.13M
EPS (Diluted)
0.4954 0.7848 0.4319 -0.4114
EPS (Diluted) Growth
+301.78% +58.42% -44.97% -195.25%
Diluted Shares Outstanding
49.46M 49.38M 49.43M 49.13M
EBITDA
36.98M 48.31M 33.22M (5.72M)
EBITDA Growth
+234.25% +30.64% -31.24% -117.22%
EBITDA Margin
+16.05% +16.99% +10.30% -1.82%

Snapshot

Average Recommendation HOLD Average Target Price 18.50
Number of Ratings 14 Current Quarters Estimate -0.575
FY Report Date 06 / 2025 Current Year's Estimate -0.808
Last Quarter’s Earnings -0.517 Median PE on CY Estimate N/A
Year Ago Earnings 0.215 Next Fiscal Year Estimate 0.336
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 6 10
Mean Estimate -0.58 0.19 -0.81 0.34
High Estimates -0.38 0.35 -0.54 1.13
Low Estimate -0.69 0.02 -1.09 -0.67
Coefficient of Variance -19.85 57.16 -25.16 183.70

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 10 10 9
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Staar Surgical - STAA

Date Name Shares Transaction Value
Apr 8, 2025 Broadwood Capital, Inc. 12,696,579 Open market or private purchase of non-derivative security Non-derivative transaction at $16.97 per share 215,460,945.63
Apr 8, 2025 Broadwood Capital, Inc. 12,696,579 Open market or private purchase of non-derivative security 0.00
Apr 8, 2025 Broadwood Capital, Inc. 13,189,210 Open market or private purchase of non-derivative security Non-derivative transaction at $15.9 per share 209,708,439.00
Apr 8, 2025 Broadwood Capital, Inc. 13,189,210 Open market or private purchase of non-derivative security 0.00
Apr 8, 2025 Broadwood Capital, Inc. 13,194,210 Open market or private purchase of non-derivative security Non-derivative transaction at $16.46 per share 217,176,696.60
Apr 8, 2025 Broadwood Capital, Inc. 13,194,210 Open market or private purchase of non-derivative security 0.00
Apr 8, 2025 Broadwood Capital, Inc. 13,320,675 Open market or private purchase of non-derivative security Non-derivative transaction at $15.58 per share 207,536,116.50
Apr 8, 2025 Broadwood Capital, Inc. 13,320,675 Open market or private purchase of non-derivative security 0.00
Apr 8, 2025 Broadwood Capital, Inc. 13,332,264 Open market or private purchase of non-derivative security Non-derivative transaction at $15.98 per share 213,049,578.72
Apr 8, 2025 Broadwood Capital, Inc. 13,332,264 Open market or private purchase of non-derivative security 0.00
Mar 17, 2025 Warren Foust Chief Operating Officer 16,350 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Magda Michna Chief Clinical, Regulatory, 12,356 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Patrick F. Williams Chief Financial Officer 16,307 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Patrick F. Williams Chief Financial Officer 56,242 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Warren Foust Chief Operating Officer 26,088 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Nathaniel B. Sisitsky General Counsel 11,654 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Magda Michna Chief Clinical, Regulatory, 18,554 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Magda Michna Chief Clinical, Regulatory, 16,119 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18 per share 290,142.00
Mar 17, 2025 Nathaniel B. Sisitsky General Counsel 27,762 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Nathaniel B. Sisitsky General Counsel 25,428 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18 per share 457,704.00

Staar Surgical in the News